Immunotherapy drug improves survival for common form of lung cancer

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1KGBdtP